Under the expanded contract, Just – Evotec Biologics will use its data-driven technology platform to develop a commercial manufacturing process for ALPN-303. The program includes upstream and downstream process, analytical method and formulation development to support the commercial manufacture of ALPN-303. Commercial process development activities will be performed at Just – Evotec Biologics’ state-of-the-art J.POD biofabrication facility, located in Redmond, WA.
J.DESIGN, Just – Evotec Biologics’ highly automated and data-driven end-to-end biologics technology platform, utilizes a series of innovative technologies based on the use of artificial intelligence, machine learning, intensified and continuous bioprocessing purpose-built for flexible applications and efficient biologics development from discovery to clinical and commercial manufacturing. The advanced Just – Evotec Biologics platform is particularly well suited for monoclonal antibodies and associated protein modalities such as Fc fusion proteins. The J.POD facility was designed to support clinical and commercial manufacturing processes while leveraging its scalable and highly flexible capability.